Brief: Nanoviricides Says NV-387 Shows Activity Against Measles Virus In Humanized Animal Model
20/10/2025 17:39
Oct 20 (Reuters) - NanoViricides Inc NNVC.A: NANOVIRICIDES: CLINICAL LEAD DRUG NV-387 HAS SHOWN STRONG ACTIVITY AGAINST MEASLES VIRUS IN A HUMANIZED ANIMAL MODEL NANOVIRICIDES: NV-387 CAN NOW BE MADE AVAILABLE FOR EMERGENCY USE APPLICATION IN MEASLES PATIENTS TO RESPOND TO SPREADING MEASLES OUTBREAKS NANOVIRICIDES: NV-387 HAS ALREADY COMPLETED PHASE I CLINICAL TRIAL IN HEALTHY SUBJECTS WITH NO REPORTED ADVERSE EVENTS Further company coverage: NNVC.A ((((Reuters.Briefs@thomsonreuters.com));))
Recent news on NanoViricides,
See all newsExplainer: What do we know about the Bundibugyo strain of the Ebola virus?
Brief: anoViricides Signs Agreement for Orphan Drug Strategy of NV-387 for Mpox, Smallpox, and Measles
Brief: Nanoviricides Says NV-387 Shows Activity Against Measles Virus In Humanized Animal Model
Brief: Nanoviricides Co's Business Not Affected By Tariff Policies Of Us Government Or Corresponding Retaliatory Policies Of Other Governments
Brief: Nanoviricides Obtained Right Of First Refusal For All Antiviral Drug Developments